AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04282603 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss and Weight Maintenance
Description: Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
Study NCT04282603 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Weight Loss and Weight Maintenance
Description: Participants will consume a 1,200 kcal/day diet for twelve weeks. This is the amount of calories most commonly provided in medical weight loss programs, and considered the maximum allowable caloric intake to induce a physiologically significant weight loss. Following the weight loss portion of the trial, participants will enter the twelve week maintenance period, during which time they will consume one serving per day in place of lunch of the same meal replacement beverage used during medical weight loss.
Study NCT01175577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chlorophyll complex, Standard Process
Description: One capsule, twice daily with meals for 28 days
Study NCT01175577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betatene, sold as Full Spectrum Carotenoid Complex
Description: One capsule per day with meals for 28 days
Study NCT01175577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small carotenoid-rich meals
Description: Single carotenoid-enriched soup or salad serving eaten daily
Study NCT01175577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil-filled capsules, one twice daily with meals
Study NCT04583163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler
Description: Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
Study NCT01936870 — intervention group
Intervention type: DRUG
Intervention: Fesoterodine (Toviaz)
Description: Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Study NCT04510818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Camrelizumab
Description: This is a single-arm study with all patients receiving these two drugs.
Study NCT02459483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse phone call
Study NCT03436082 — intervention group
Intervention type: DEVICE
Intervention: A mobile health platform
Description: Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
Study NCT00936923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: patients will take furosemide 60 or 120mg oral per day for 1 years .
Study NCT00114517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17B-estradiol
Description: Oral 17B-estradiol 1 mg daily
Study NCT00114517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral 17B-estradiol placebo daily
Study NCT01931319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous baclofen
Study NCT03669341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath Hold (DIBH)
Description: human-based DIBH method with short-term breath-hold training
Study NCT03669341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Percussive Ventilation (HFPV)
Description: device-based HFPV technique
Study NCT02178137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerien
Study NCT02178137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine/Chondroitin
Study NCT02178137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01796366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
Study NCT01796366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: S.c placebo administered in combination with insulin 338
Study NCT01796366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
Study NCT01796366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral placebo administered in combination with s.c. insulin glargine
Study NCT04437134 — intervention group
Intervention type: OTHER
Intervention: On-line exercise and education
Description: Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. Patients are instructed in how to use alternative equipment at home for each exercise if necessary prior to the first on-line exercise session.~Education:~Patients attend two to three on-line educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment.
Study NCT04437134 — intervention group
Intervention type: OTHER
Intervention: On-site exercise and education
Description: Exercise:~Exercise is performed twice weekly for 6 weeks. Each exercise session lasts approximately 60 min. and consists of three parts; warm-up (10 min.), neuromuscular exercises (40 min.), and cool-down/stretching (10 min.). The neuromuscular exercises include exercises for core stability, postural orientation, function and leg muscle strength. Exercises are performed in 2-3 sets with 10-15 repetitions with three levels of difficulty described. The exercises follow the standardized GLA:D exercise protocol. The exercise sessions are delivered at physiotherapy clinics in Denmark.~Education:~Patients attend two to three on-site educational sessions at the start of each GLA:D program. The educational sessions focus on disease-management and self-help strategies, The educational sessions focus on disease-management and self-help strategies, including OA disease features and symptoms, treatment options, and exercise and physical activity as treatment.
Study NCT02198404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation with propofol
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study NCT04073979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral implant is implanted in the Tricuspid valve
Study NCT03416543 — intervention group
Intervention type: OTHER
Intervention: Puncture
Description: Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
Study NCT02495519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg/day until disease progression
Study NCT00774267 — intervention group
Intervention type: DRUG
Intervention: BZA 20 mg/CE 0.45 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study NCT00774267 — intervention group
Intervention type: DRUG
Intervention: BZA 20 mg/CE 0.625 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study NCT00774267 — intervention group
Intervention type: DRUG
Intervention: Raloxifene 60 mg
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study NCT00774267 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Study NCT01006993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter
Description: NeuroFlo™ catheter 45 minute treatment
Study NCT01528969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
Study NCT01528969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sorbitol
Description: Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
Study NCT01908062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Naltrexone
Study NCT01908062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As usual
Study NCT00551278 — intervention group
Intervention type: DEVICE
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required.
Study NCT03057483 — intervention group
Intervention type: BIOLOGICAL
Intervention: Seasonal Influenza vaccine
Description: Seasonal Influenza vaccine
Study NCT01993797 — intervention group
Intervention type: OTHER
Intervention: Lung US
Study NCT05091775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol is used to treat and prevent mild to moderate acute fissure disease
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Study NCT05091775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Asacol is used to treat and prevent mild to moderate acute fissure disease
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Study NCT02086500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram of prehospital Tranexamic Acid
Study NCT02086500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline Control
Study NCT00643721 — intervention group
Intervention type: OTHER
Intervention: dehydration
Description: dehydration to 3% and 5% loss of total body water
Study NCT00990197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
Study NCT04803396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF2755A
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).
Study NCT04803396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose administration on D1
Study NCT04509219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Injection
Description: methylprednisolone pulse therapy, 30mg/kg, with maximal dose of 1000mg/day, for continue 3 days.
Study NCT03071042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
Study NCT03071042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Study NCT01847326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01847326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT01847326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01847326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Given PO
Study NCT01847326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT01847326 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT01847326 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hyperfractionated radiation therapy
Description: Undergo hyperfractionated radiation therapy
Study NCT01847326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Vehicle used to dilute the powder for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT01416324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg GSK2330672
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study NCT03072108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bonolive
Description: 2 caps per day of Bonolive
Study NCT03072108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 caps per day of Placebo
Study NCT04655352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Bacillus subtilis MB40
Description: 1-week placebo (maltodextrin and excipients) lead-in followed by 250 mg capsule (5 billion CFU/capsule) administered twice daily for 21 days
Study NCT03498404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
Study NCT03498404 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: scaling and root planing
Description: Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
Study NCT00475956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet multiple ascending doses 20, 30 or 45 mg
Study NCT00475956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet multiple ascending doses 125 mg or 175 mg
Study NCT02291458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: 9 gram L-arginine / day for 6 weeks
Study NCT02291458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 gram placebo / day for 6 weeks
Study NCT01470950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motionmaker
Description: 3 times per week, FES Training on the Motionmaker device, for 6 months
Study NCT02817568 — intervention group
Intervention type: OTHER
Intervention: Drawing Blood
Description: Drawing Blood for genetic analysis
Study NCT04395742 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Only data collection
Study NCT00867815 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diagnostic procedures
Description: The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
Study NCT00245752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
Study NCT00245752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
Study NCT04326283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (0.5 mg)
Description: 0.5 mg/day
Study NCT04326283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (1 mg)
Description: 1 mg/day
Study NCT04326283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole (100 mg)
Description: 100 mg/day (50 mg twice)
Study NCT04182646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartz Balloon
Description: The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
Study NCT00273793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: incentives are available for reduced smoking on each study visit which occur each weekday.